This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Clinical Information​Stroke Prevention in Atrial Fibrillation​Morbidity and Mortality​Efficacy​Aristophanes​Safety​Real-world Data​Guideline recommendations​Persistence and Adherence​Dosing​Summary​Venous Thromboembolism TreatmentEfficacySafety​Real-world Data​Guideline recommendationsDosing​Venous Thromboembolism PreventionEfficacy​Safety​Dosing​Eliquis Important Safety InformationEliquis Abbreviated Prescribing Information (2.5 mg)​Eliquis Abbreviated Prescribing Information (5 mg) Support & Services​ Support & Services​ Self-detail presentations​ Webinars​ Videos​
Eliquis® offers a short 7-day treatment initiation period and a lower dose for extended therapy 1
  • The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10mg taken orally twice daily for the first 7 days followed by 5mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).1
  • The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5mg taken orally twice daily. When prevention of recurrent DVT and PE is indicated, the 2.5mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5mg twice daily.1​
Study design​

AMPLIFY: In the study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR≥ 2) and warfarin (target INR range 2.0-3.0) orally for 6 months. The mean age was 56.9 years and 89.8% of randomised patients had unprovoked Venous Thromboembolism events.3​

AMPLIFY-EXT: In the study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment.2​
AMPLIFY: Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy; AMPLIFY-EXT: Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism; BID: twice daily; VTE: venous thromboembolism.​

References: 1. ELIQUIS® 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Eng J Med. 2013;368(8):699-708. 3. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.​
Explore more​SPAF Dosing​ Learn more Loading
Click here for Eliquis® 2.5mg Prescribing Information

Click here for Eliquis® 5mg Prescribing Information
Invalidation Date : 21/08/2024​
Quick Links
SPAF Guideline recommendations​
Learn moreLoading
VTE treatment Efficacy​
Learn more Loading

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No